#BEGIN_DRUGCARD DB01279

# AHFS_Codes:
Not Available

# ATC_Codes:
A16AB08

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Naglazyme
Naglazyme (BioMarin Pharmaceuticals)

# CAS_Registry_Number:
552858-79-4

# ChEBI_ID:
Not Available

# Chemical_Formula:
C2534H3851N691O719S16

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
Not Available

# Creation_Date:
2007-05-16 16:31:52 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Galsufase is a variant form of the polymorphic human enzyme N-acetylgalactosamine 4-sulfatase of recombinant DNA origin. Galsulfase is a glycoprotein with a molecular weight of approximately 56 kD. The recombinant protein is comprised of 495 amino acids and contains six asparagine-linked glycosylation sites, four of which carry a bis mannose-6-phosphate manose7 oligosaccharide for specific cellular recognition. Post-translational modification of Cys53 produces the catalytic amino acid residue Ca-formylglycine, which is required for enzyme activity and is conserved in all members of the sulfatase enzyme family.

# Dosage_Forms:
Solution	Intravenous drip

# Drug_Category:
Enzyme Replacement Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Biotech
Investigational

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Galsulfase

# HET_ID:
Not Available

# Half_Life:
9 (6 to 21) minutes during the first week of treatment, 26 (8 to 40) minutes by the 24th week.

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
For the treatment of adults and children with Mucopolysaccharidosis VI.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1279

# Mechanism_Of_Action:
Galsulfase supplies recombinant-engineered galsulfase, a normal variant form of the polymorphic human enzyme, N-acetylgalactosamine 4-sulfatase. It is a lysosomal hydrolase that catalyzes the cleavage of the sulfate ester from terminal N-acetylgalactosamine 4-sulfate residues of GAG chondroitin 4-sulfate and dermatan sulfate. Increased catabolism of GAG in turn reduces systemic dermatan sulfate accumulation, thereby reducing the primary symptoms of MPS VI.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
56000.0000

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164746235

# Pharmacology:
Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the catabolism of GAG. Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) is characterized by the absence or marked reduction in N-acetylgalactosamine 4-sulfatase. The sulfatase activity deficiency results in the accumulation of the GAG substrate dermatan sulfate, throughout the body. This accumulation leads to widespread cellular, tissue, and organ dysfunction. Galsulfase is intended to provide an exogenous enzyme that will be taken up into lysosomes and increase the catabolism of GAG. Galsulfase uptake by cells into lysosomes is most likely mediated by the binding of mannose-6-phosphate-terminated oligosaccharide chains of galsulfase to specific mannose-6-phosphate receptors.

# Predicted_LogP_Hydrophobicity:
Not Available

# Predicted_LogS:
Not Available

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB01279

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/naglazyme.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
solid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
There is no experience with overdose of galsulfase.

# Update_Date:
2011-08-02 23:42:41 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Galsulfase

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
18709516	White JT, Argento Martell L, Prince WS, Boyer R, Crockett L, Cox C, Van Tuyl A, Aguilera A, Foehr E: Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase). AAPS J. 2008 Sep;10(3):439-49. Epub 2008 Aug 16.
19142150	Tifft C, Proud V, Levy P, DeMarco K, Nicely H, Turbeville S: Enzyme replacement therapy in the home setting for mucopolysaccharidosis VI: a survey of patient characteristics and physicians' early findings in the United States. J Infus Nurs. 2009 Jan-Feb;32(1):45-52.
20670992	Dogan M, Cesur Y, Peker E, Oner AF, Dogan SZ: Thrombocytopenia associated with galsulfase treatment. Hum Exp Toxicol. 2010 Jul 29.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6076

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
Dermatan sulfate

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

# Drug_Target_2_Cellular_Location:
Cytoplasm. Endosome. Note=Membrane associated on endosomes. Detected in the envelope and the core of

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
18709516	White JT, Argento Martell L, Prince WS, Boyer R, Crockett L, Cox C, Van Tuyl A, Aguilera A, Foehr E: Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase). AAPS J. 2008 Sep;10(3):439-49. Epub 2008 Aug 16.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
M6PRBP1

# Drug_Target_2_GenBank_ID_Gene:
AF057140

# Drug_Target_2_GenBank_ID_Protein:
3095186

# Drug_Target_2_GeneCard_ID:
M6PRBP1

# Drug_Target_2_Gene_Name:
PLIN3

# Drug_Target_2_Gene_Sequence:
>1305 bp
ATGTCTGCCGACGGGGCAGAGGCTGATGGCAGCACCCAGGTGACAGTGGAAGAACCGGTA
CAGCAGCCCAGTGTGGTGGACCGTGTGGCCAGCATGCCTCTGATCAGCTCCACCTGCGAC
ATGGTGTCCGCAGCCTATGCCTCCACCAAGGAGAGCTACCCGCACGTCAAGACTGTCTGC
GACGCAGCAGAGAAGGGAGTGAGGACCCTCACGGCGGCTGCTGTCAGCGGGGCTCAGCCG
ATCCTCTCCAAGCTGGAGCCCCAGATTGCATCAGCCAGCGAATACGCCCACAGGGGGCTG
GACAAGTTGGAGGAGAACCTCCCCATCCTGCAGCAGCCCACGGAGAAGGTCCTGGCGGAC
ACCAAGGAGCTTGTGTCGTCTAAGGTGTCGGGGGCCCAAGAGATGGTGTCTAGCGCCAAG
GACACGGTGGCCACCCAATTGTCGGAGGCGGTGGACGCGACCCGCGGTGCTGTGCAGAGC
GGCGTGGACAAGACAAAGTCCGTAGTGACCGGCGGCGTCCAATCAGTCATGGGCTCCCGC
TTGGGCCAGATGGTGCTGAGTGGGGTCGACACGGTGCTGGGGAAGTCGGAGGAGTGGGCG
GACAACCACCTGCCCCTTACGGATGCCGAACTGGCCCGCATCGCCACATCCCTGGATGGC
TTCGACGTCGCGTCCGTGCAGCAGCAGCGGCAGGAACAGAGCTACTTCGTACGTCTGGGC
TCCCTGTCGGAGAGGCTGCGGCAGCACGCCTATGAGCACTCGCTGGGCAAGCTTCGAGCC
ACCAAGCAGAGGGCACAGGAGGCTCTGCTGCAGCTGTCGCAGGCCCTAAGCCTGATGGAA
ACTGTCAAGCAAGGCGTTGATCAGAAGCTGGTGGAAGGCCAGGAGAAGCTGCACCAGATG
TGGCTCAGCTGGAACCAGAAGCAGCTCCAGGGCCCCGAGAAGGAGCCGCCCAAGCCAGAG
CAGGTCGAGTCCCGGGCGCTCACCATGTTCCGGGACATTGCCCAGCAACTGCAGGCCACC
TGTACCTCCCTGGGGTCCAGCATTCAGGGCCTCCCCACCAATGTGAAGGACCAGGTGCAG
CAGGCCCGCCGCCAGGTGGAGGACCTCCAGGCCACGTTTTCCAGCATCCACTCCTTCCAG
GACCTGTCCAGCAGCATTCTGGCCCAGAGCCGTGAGCGTGTCGCCAGCGCCCGCGAGGCC
CTGGACCACATGGTGGAATATGTGGCCCAGAACACACCTGTCACGTGGCTCGTGGGACCC
TTTGCCCCTGGAATCACTGAGAAAGCCCCGGAGGAGAAGAAATAG

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
10393528	Than NG, Sumegi B, Than GN, Kispal G, Bohn H: Cloning and sequencing of human oncodevelopmental soluble placental tissue protein 17 (PP17): homology with adipophilin and the mouse adipose differentiation-related protein. Tumour Biol. 1999 Jul-Aug;20(4):184-92.
6856484	Bohn H, Kraus W, Winckler W: Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17). Oncodev Biol Med. 1983;4(5):343-50.
9590177	Diaz E, Pfeffer SR: TIP47: a cargo selection device for mannose 6-phosphate receptor trafficking. Cell. 1998 May 1;93(3):433-43.
9874244	Than NG, Sumegi B, Than GN, Kispal G, Bohn H: Cloning and sequence analysis of cDNAs encoding human placental tissue protein 17 (PP17) variants. Eur J Biochem. 1998 Dec 1;258(2):752-7.

# Drug_Target_2_HGNC_ID:
HGNC:16893

# Drug_Target_2_HPRD_ID:
04080

# Drug_Target_2_ID:
956

# Drug_Target_2_Locus:
19p13.3

# Drug_Target_2_Molecular_Weight:
47047

# Drug_Target_2_Name:
Mannose-6-phosphate receptor-binding protein 1

# Drug_Target_2_Number_of_Residues:
434

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF03036	Perilipin

# Drug_Target_2_Protein_Sequence:
>Mannose-6-phosphate receptor-binding protein 1
MSADGAEADGSTQVTVEEPVQQPSVVDRVASMPLISSTCDMVSAAYASTKESYPHIKTVC
DAAEKGVRTLTAAAVSGAQPILSKLEPQIASASEYAHRGLDKLEENLPILQQPTEKVLAD
TKELVSSKVSGAQEMVSSAKDTVATQLSEAVDATRGAVQSGVDKTKSVVTGGVQSVMGSR
LGQMVLSGVDTVLGKSEEWADNHLPLTDAELARIATSLDGFDVASVQQQRQEQSYFVRLG
SLSERLRQHAYEHSLGKLRATKQRAQEALLQLSQALSLMETVKQGVDQKLVEGQEKLHQM
WLSWNQKQLQGPEKEPPKPEQVESRALTMFRDIAQQLQATCTSLGSSIQGLPTNVKDQVQ
QARRQVEDLQATFSSIHSFQDLSSSILAQSRERVASAREALDHMVEYVAQNTPVTWLVGP
FAPGITEKAPEEKK

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Required for the transport of mannose 6-phosphate receptors (MPR) from endosomes to the trans-Golgi network

# Drug_Target_2_SwissProt_ID:
O60664

# Drug_Target_2_SwissProt_Name:
PLIN3_HUMAN

# Drug_Target_2_Synonyms:
47 kDa MPR-binding protein
47 kDa mannose 6-phosphate receptor-binding protein
Cargo selection protein TIP47
PP17
Placental protein 17

# Drug_Target_2_Theoretical_pI:
5.11

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB01279
